GlassScriptPhysician profile
Deepika Narasimha
NPI 1932499373
$2,121.78
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $344 · 2021: $60.54 · 2022: $99.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $475.84 | 2019 | |
| Cardiovascular Systems INC. | $284.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $250.75 | 2019-2022 | |
| Philips North America LLC | $140.61 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.45 | 2019 | |
| Penumbra, INC. | $126.20 | 2019-2020 | |
| Terumo Medical Corporation | $123.42 | 2019 | |
| Medtronic Vascular, INC. | $99.41 | 2019 | |
| Boston Scientific Corporation | $98.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $92.53 | 2019-2020 | |
| Pfizer INC. | $67.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.00 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $34.10 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $33.48 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.13 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.70 | 2020 | |
| Amgen INC. | $13.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Narasimha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.